Introduction and Phase 3 COMMANDS Trial

Twice-daily radiotherapy prolongs survival vs once-daily radiation among those with LS-SCLC, even with the incorporation of immunotherapy.

Experts discuss considerations for improving the care of patients with prostate, kidney, and bladder cancer in community-based practices at World GU 2025.

It may be possible to use anastrozole plus palbociclib, trastuzumab, and pertuzumab in place of chemotherapy in the frontline setting for hormone receptor–positive, HER2-positive metastatic breast cancer, says Amy Tiersten, MD.

Geraldine O’Sullivan Coyne, MD, PhD, MRCPI, discusses how the START center may expand access to novel therapies for patients who reside in a community setting.

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.